Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 1.00 |
| ▸ | LMNA | P02545 | 9/20 | 1.00 |
| ▸ | TSHR | P16473 | 9/20 | 0.88 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.88 |
| ▸ | TP53 | P04637 | 6/20 | 0.84 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.84 |
| ▸ | RAB9A | P51151 | 2/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12698265 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNATSHRNPSR1TP53 | |
| SCHEMBL29433738 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNATSHRNPSR1TP53 | |
| SCHEMBL29433753 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNATSHRNPSR1TP53 | |
| SCHEMBL17226016 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNATSHRNPSR1TP53 | |
| SCHEMBL21643939 | 0.93 | TSHR (1.00) | SMN1; SMN2LMNATSHRNPSR1TP53 | |
| SCHEMBL14842661 | 0.91 | LMNA (1.00) | SMN1; SMN2LMNATSHRNPSR1TP53 | |
| SCHEMBL18511516 | 0.90 | LMNA (0.90) | SMN1; SMN2LMNATSHRNPSR1TP53 | |
| SCHEMBL12469836 | 0.88 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNATSHRNPSR1TP53 | |
| SCHEMBL29433766 | 0.88 | SMN1; SMN2 (0.79) | SMN1; SMN2LMNATSHRNPSR1TP53 | |
| SCHEMBL18522859 | 0.88 | SMN1; SMN2 (0.79) | SMN1; SMN2LMNATSHRNPSR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458132-B2 | Quinolin-2(1H)-one inhibitors of Late SV40 Factor | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220062272-A1 | QUINOLIN-2(1H)-ONE INHIBITORS OF LATE SV40 FACTOR | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220062272-A1 | QUINOLIN-2(1H)-ONE INHIBITORS OF LATE SV40 FACTOR | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-03 | — | — | US | disclosed |
| US-20200039996-A1 | LATE SV40 (LSF) INHIBITORS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-02-06 | — | — | US | disclosed |
| WO-2020028757-A1 | LATE SV40 FACTOR (LSF) INHIBITORS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-02-06 | — | — | WO | disclosed |
| US-10392398-B2 | Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-10392398-B2 | Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180051033-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2018-02-22 | — | — | US | disclosed |
| US-20180051033-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2018-02-22 | — | — | US | disclosed |
| US-20180051033-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2018-02-22 | — | — | US | disclosed |
| US-9399644-B2 | [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer | TRUSTEES OF BOSTON UNIVERSITY (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150344491-A1 | [1,3] DIOXOLO [4,5-G] QUINOLINE-6(5H)THIONE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER | TRUSTEES OF BOSTON UNIVERSITY (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344491-A1 | [1,3] DIOXOLO [4,5-G] QUINOLINE-6(5H)THIONE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER | TRUSTEES OF BOSTON UNIVERSITY (US) | 2015-12-03 | — | — | US | disclosed |
| US-9175001-B2 | [1,3] dioxolo [4,5-g] [1,2,4] triazolo [1,5-a] quinoline derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer | TRUSTEES OF BOSTON UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-9175001-B2 | [1,3] dioxolo [4,5-g] [1,2,4] triazolo [1,5-a] quinoline derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer | TRUSTEES OF BOSTON UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140249312-A1 | [1,3]DIOXOLO[4,5-G]QUINOLINE-6(5H)THIONE AND [1,3]DIOXOLO[4,5-G][1,2,4]TRIAZOLO[1,5-A]QUINOLINE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER | TRUSTEES OF BOSTON UNIVERSITY (US) | 2014-09-04 | — | — | US | disclosed |
| US-20130324570-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-12-05 | — | — | US | disclosed |
| WO-2013052465-A1 | [1,3]DIOXOLO[4,5-G]QUINOLINE-6(5H)THIONE AND [1,3]DIOXOLO[4,5-G][1,2,4]TRIAZOLO[1,5-A]QUINOLINE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-04-11 | — | — | WO | disclosed |
| WO-2012050985-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012050985-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062272-A1 | QUINOLIN-2(1H)-ONE INHIBITORS OF LATE SV40 FACTOR | NUTF2, UBTF, TUBB1 | SMN1; SMN2 4593/4885LMNA 576/4885TSHR 4267/4885 |
| US-20140249312-A1 | [1,3]DIOXOLO[4,5-G]QUINOLINE-6(5H)THIONE AND [1,3]DIOXOLO[4,5-G][1,2,4]TRIAZOLO[1,5-A]QUINOLINE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER | GTF3C5, GTF3C2, GTF3C1 | SMN1; SMN2 4828/4885LMNA 701/4885TSHR 2194/4885 |
| US-20150344491-A1 | [1,3] DIOXOLO [4,5-G] QUINOLINE-6(5H)THIONE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER | GTF3C5, GTF2F1, GTF3C2 | SMN1; SMN2 4821/4885LMNA 738/4885TSHR 2266/4885 |
| US-20130324570-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | GTF2F1, HDGF, GTF2F2 | SMN1; SMN2 4669/4885LMNA 806/4885TSHR 3997/4885 |
| US-20200039996-A1 | LATE SV40 (LSF) INHIBITORS | DNMT1, ASF1A, DOT1L | SMN1; SMN2 3759/4885LMNA 399/4885TSHR 3880/4885 |
| US-20180051033-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | GTF2F1, HDGF, GTF3C5 | SMN1; SMN2 4673/4885LMNA 861/4885TSHR 3901/4885 |
| US-10392398-B2 | Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics | GTF2F1, HDGF, GTF3C5 | SMN1; SMN2 4673/4885LMNA 861/4885TSHR 3901/4885 |
| US-11458132-B2 | Quinolin-2(1H)-one inhibitors of Late SV40 Factor | NUTF2, UBTF, TUBB1 | SMN1; SMN2 4593/4885LMNA 576/4885TSHR 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.